Lead Product(s) : DB007
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : DotBio
Deal Size : Undisclosed
Deal Type : Collaboration
Bora Biologics, DotBio Enter Strategic CMC Development Collaboration
Details : The collaboration aims to advance the development of DotBio’s Tri-Specific Antibody DB007 for the treatment of Cancer.
Product Name : DB007
Product Type : Antibody
Upfront Cash : Undisclosed
January 09, 2025
Lead Product(s) : DB007
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : DotBio
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Study Phase : Approved
Recipient : Pyros Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Bora Expands Rare Disease Portfolio with Pyros Pharma Acquisition
Details : Through the acquisition of US-based Pyros, Bora will expand his pipelines by adding some candidates such as Vigafyde (vigabatrin), which is indicated for the treatment of infantile spasms.
Product Name : Vigafyde
Product Type : Small molecule
Upfront Cash : Undisclosed
October 25, 2024
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Highest Development Status : Approved
Recipient : Pyros Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Recipient : Upsher-Smith Laboratories
Deal Size : Undisclosed
Deal Type : Acquisition
Bora Pharmaceuticals Completes Acquisition of Upsher-Smith
Details : Through the acquisition, Bora will commercialize Amantadine HCl-Generic, which is an NMDA receptor inhibitor. It is indicated for the treatment of influenza A infections and Parkinsonism.
Product Name : Amantadine HCl-Generic
Product Type : Small molecule
Upfront Cash : Undisclosed
April 01, 2024
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Recipient : Upsher-Smith Laboratories
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Recipient : Upsher-Smith Laboratories
Deal Size : $210.0 million
Deal Type : Acquisition
CDMO Bora Pharmaceuticals Buys Generics Manufacturer Upsher-Smith for $210M
Details : Bora acquires Upsher-Smith’s product portfolio, including Amantadine hydrochloride for treating influenza A virus infections.
Product Name : Amantadine HCl-Generic
Product Type : Small molecule
Upfront Cash : Undisclosed
January 18, 2024
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Recipient : Upsher-Smith Laboratories
Deal Size : $210.0 million
Deal Type : Acquisition
Lead Product(s) : CT-G20
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Celltrion
Deal Size : Undisclosed
Deal Type : Partnership
Bora and Celltrion Join Forces To Distribute Oral Drugs Across APAC
Details : Under the partnership, Bora will manufacture and commercialize a range of oral dosage form drugs (OSD), including CT-G20, a hypertrophic cardiomyopathy treatment candidate, across the APAC region.
Product Name : CT-G20
Product Type : Small molecule
Upfront Cash : Undisclosed
April 06, 2023
Lead Product(s) : CT-G20
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Celltrion
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Foslinanib,Sorafenib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : TaiRx
Deal Size : Undisclosed
Deal Type : Partnership
Bora Pharmaceuticals Partners with TaiRx
Details : CVM-1118 (foslinanib) is a new small molecule chemical entity and a potential anti-cancer agent in numerous human cancer cell lines with strong anti-cancer activity, high safety margin, and multiple mechanisms of actions in targeting cancer-specific fact...
Product Name : CVM-1118
Product Type : Small molecule
Upfront Cash : Undisclosed
September 27, 2022
Lead Product(s) : Foslinanib,Sorafenib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : TaiRx
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : L-Lactic Acid,Citric Acid,Potassium Bitartrate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved
Recipient : Evofem Biosciences
Deal Size : Undisclosed
Deal Type : Partnership
Details : Initially, Bora will manufacture Phexxi for nations currently considering formal regulatory approval of Phexxi (L-lactic Acid), for the prevention of pregnancy, including Mexico and Nigeria.
Product Name : Phexxi
Product Type : Small molecule
Upfront Cash : Undisclosed
May 10, 2022
Lead Product(s) : L-Lactic Acid,Citric Acid,Potassium Bitartrate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Recipient : Evofem Biosciences
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Undisclosed
Recipient : Kyowa Pharmaceutical Industry
Deal Size : Undisclosed
Deal Type : Partnership
Details : Upon PMDA’s approval, Bora will be the commercial manufacturing site for the generic product production. Bora Pharmaceuticals’ sites already have an excellent track record with many regulatory agencies around the world.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 05, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Undisclosed
Recipient : Kyowa Pharmaceutical Industry
Deal Size : Undisclosed
Deal Type : Partnership
KEY SERVICES
Reset All
Bora Pharmaceuticals- Making success more certain.
